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a  b  s  t  r  a  c  t
Introduction: Advances in the treatment of HIV infection in the last decades have increased
life expectancy of these patients and raise the question of what kind of effect chronic
infection and its treatment might exert on the behavior of age-related conditions such as
neurodegenerative diseases.
Patient data: We  performed a retrospective analysis of patients’ records to assess the fre-
quency of the association between HIV infection and parkinsonian symptoms in our hospital
population. Among 249 records we identiﬁed four individuals with reported parkinsonian
symptoms initiated after HIV diagnosis. Three of them had no other identiﬁable cause of
secondary parkinsonism. All had symptom onset before the age of 60. Based on this study
sample one could estimate an incidence rate of nearly 101 per 100.000 person/year, which
is  similar to the risk of Parkinson’s disease in the general population above 70 years.
Discussion: These ﬁndings suggest that HIV infected individuals might be at a higher risk for
developing parkinsonism as a manifestation of early neurodegeneration. Prospective andlarger studies are needed to address this particular association and its characteristics.
©  2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
agent capable of triggering an early presentation of neurode-ntroduction
anifestations of neurodegenerative conditions have become
ncreasingly important in the evaluation of HIV-infected
HIV+) patients with chronic infection and adequate response
o antiretroviral therapy (ART). This could be justiﬁed by the
ncreasing life expectancy of this population, but studies also
ndicate that these individuals are at higher risk of developing
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symptoms of neurologic conditions earlier than the general
population even in the absence of immunosuppression or
opportunistic infections.1 Research on this area has tried to
deﬁne if chronic asymptomatic HIV infection could be the
direct cause of these symptoms or some kind of inductiongenerative diseases that would develop regardless at older age,
and whether treatment choices for HIV inﬂuence the occur-
rence of these conditions as protective or harmful agents.
lsevier Editora Ltda. This is an open access article under the CC
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Based on the ﬁndings of Tisch and Brew2 we  are involved in
a study to assess the frequency of the association between
HIV infection and parkinsonism in our population. This is a
retrospective review of patient records from our Infectious Dis-
ease and Neurology clinics. Herein we  present data from HIV+
patients currently followed, among which we identiﬁed cases
of parkinsonism initiated after the diagnosis of HIV.
Patient  data
The study design has been approved by the Pedro Ernesto
University Hospital Ethics Committee. We  retrospectively ana-
lyzed, from April to October 2015, a total of 249 records from
patients diagnosed with HIV, of which 36.6% were females
and 63.4% males, with a mean age of 47 years and a mean
length of disease of 12 years (0–33 years). Four individuals
were diagnosed with parkinsonism, but one of them had neu-
rotoxoplasmosis lesions that could explain the symptoms.
The other three cases were men  who  had at the time of
the parkinsonism presentation ages between 46 and 55 years
and good adherence to ART with reported plasma viral loads
below 50 copies/mL and CD4+ cell count above 350 per mm3.
None of them had a history of exposure to substances that
could induce secondary parkinsonism, (neuroleptics, calcium
channel blockers, or antiemetics). Neuroimaging disclosed a
retrocerebellar cyst in patient C, and was unremarkable on
the other two. At the beginning of parkinsonian symptoms, all









Fig. 1 – Timelines showing evolution to parkinsonism after HIV d
The timelines show the evolution to clinical manifestations of pa
start of ART, LD initiation is also highlighted. All of them had at 
(<50 copies/mL) and CD4+ cell count above 350 per mm3. 1 6;2  0(5):499–501
patients were on the same ART as in the last follow-up visit.
Patient A was under ART with tenofovir (TDF), lamivudine
(3TC), atazanavir (ATV) and ritonavir (r), had no cognitive com-
plaints and a last reported Mini Mental State Exam (MMSE) of
29/30; he had mild bilateral bradykinesia in upper extremities
and postural, rest and kinetic tremor in the right arm that did
not interfere with activities of daily living and therefore was
not on any antiparkinsonian drug. Patient B was on zidovudine
(AZT), 3TC and efavirenz (EFV), had no cognitive complaints
and a MMSE of 30/30; he presented mild rigidity and bradyki-
nesia in the right side, moderate neck rigidity, reduced arm
swing, anteﬂexion of the trunk and postural instability. Patient
C was also under treatment with AZT, 3TC and EFV, had no cog-
nitive complaints and a MMSE of 27/30; he had mild symmetric
bilateral rigidity and bradykinesia, mild rest tremor in the right
arm, mild bilateral postural tremor in upper extremities and
reduced arm swing. Patients B and C had a good response to
levodopa (LD) even at low dosages (both with 200 mg/day) and
no signiﬁcant side effects. Fig. 1 displays individual timelines
highlighting the most relevant events from HIV diagnosis until
last recorded follow-up.
DiscussionThe incidence of neurodegenerative conditions, such as
Parkinson’s disease (PD), increases with age and HIV chronic









iagnosis, highlighting initiation of ART and LD treatments.
rkinsonism in each patient after the diagnosis of HIV and
the beginning of the symptoms adequate viral control
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heir risk even in younger individuals. The mechanisms
hereby HIV favors the occurrence of degenerative changes
n the central nervous system (CNS) were suggested in several
xperimental models. Disruption of the blood-brain bar-
ier function as a fundamental mechanism facilitating the
ntrance of HIV in the CNS followed by a conjunction of direct
nd indirect viral factors, such as viral proteins gp120, tat
nd vpR has been observed. Also, cytokines and chemokines
roduced by macrophages/microglia and activated astrocytes
TNF-,  IL-6, GM-CSF, IL-1) which induce neuronal dam-
ge mediated by oxidative stress, excitotoxicity and distress
f cellular defense mechanisms (heat-shock proteins – HSP,
haperones and ubiquitin-proteasome system) with conse-
uent apoptosis.3–5 Some antiretrovirals are also studied as
otential agents of cellular damage, particularly protease
nhibitors through inhibition of P-glycoprotein system,3 and
high” CNS penetration potential of combined ART might play
 neurotoxic role6 although this is yet to be determinate. Khan-
ou et al. used immunohistochemical assays in cerebral tissue
erived from autopsies of 73 HIV+ individuals aged 50 years
r older. A higher expression of -synuclein in the substan-
ia nigra compared with control samples (16% vs 0%) even
n asymptomatic patients was found, suggesting a relation
etween these neurotoxic mechanisms and the physiopathol-
gy of PD and other neurodegenerative diseases.7
In our study we  have found three cases of HIV+ patients
nder effective ART who began PD symptoms prior to 60 years
f age, with an estimated incidence rate of nearly 101 cases per
00,000 person/year which is similar to the incidence in those
bove 70 years in the general population.8 However studies
ith larger sample sizes are needed to make statistical rele-
ant considerations. Other important limitations of our study
ere the incomplete or absent information (i.e. exposure to
nvironmental toxins, family history) due to the retrospective
ature of the study, unavailability of functional neuroimag-
ng (DAT-SCAN, SPECT), and the lack of previous cerebrospinal
uid (CSF) analyses from the three reported patients.
We believe that the cases herein described are illustrative of
arkinsonism as an early manifestation of neurodegeneration
nduced/facilitated by chronic asymptomatic HIV infection
espite adequate ART. This report adds up to the few patients
lready described in the literature in an attempt to better char-
cterize causal relation and clinical features of this condition.
linically the reported cases of parkinsonism initiated after
he prescription of adequate ART in HIV+ individuals including
he ones described here, present similar signs and symptoms
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of idiopathic PD, with variable response to LD.2,9 To our con-
cern there are no prospective studies to date evaluating long
term prognostic aspects of these patients.
Difﬁculties to draw deﬁnitive conclusions from clinical
research focused in the identiﬁcation of neurodegenerative
disorders and their association with HIV is hindered by vari-
ations of gender, age, and comorbidities compared with the
general population, along with selection and survival biases
in the studied samples.10 Prospective multicenter studies
enrolling a larger number of patients are necessary to address
the uncertainties related to causal factors, clinical character-
istics, and prognostic aspects of these conditions.
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